Descripción del proyecto
Un nuevo fármaco biológico contra enfermedades autoinmunitarias
La artritis reumatoide (AR) y la artritis idiopática juvenil (AIJ) son enfermedades crónicas y discapacitantes que afectan respectivamente a cerca del 1 % de la población adulta y a miles de niños en todo el mundo. Los tratamientos actuales consisten en la supresión del sistema inmunitario del paciente y no tienen éxito en casi el 30 % de los pacientes. El objetivo del proyecto Notid, financiado con fondos europeos, es crear un nuevo fármaco dirigido a proteínas para tratar enfermedades inflamatorias crónicas. Los resultados preliminares son prometedores e indican que el fármaco puede utilizarse para tratar una serie de enfermedades autoinmunitarias y autoinflamatorias, y así mejorar la calidad de vida de los pacientes.
Objetivo
Lipum AB has discovered a novel target protein for treatment of chronic inflammatory diseases. We are now developing a biological drug that will inhibit the target molecule. We propose an entirely new therapeutic mode of action as an alternative to current therapeutics that do not provide adequate response in as much as 1/3 of patients. Our research and preclinical results indicate that our approach can be applied for treatment of an array of autoimmune and autoinflammatory conditions, and that the suppression of the patient immune system can be avoided, which otherwise is a common negative side effect limiting treatment options. Currently, Lipum is focused on delivering a humanised candidate drug. Our aim is to to reach a drug development phase where toxicology and safety tests can be started and establish collaborations needed to proceed with the clinical studies. Within the lifecycle of this project, Lipum will focus on providing preclinical evidence, securing IP and reaching out to partners interested in exploitation of our approach for the treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. These are chronic and debilitating conditions that affect around 1% of adult population (RA) or thousands of children (JIA) worldwide. Both RA and JIA are important cause of disability and generate high costs of healthcare and lost productivityLipum AB is a Swedish SME founded in 2010 with the aim to bring to the market a new biological drug for chronic inflammatory diseases. An effective and safe alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), or Inflammatory Bowel Disease (IBD), and by the rheumatology opinion leaders that have been highlighting the unmet clinical need in this domain. Apart from the patients’ well-being and quality of life, chronic inflammatory diseases incur high social costs of healthcare and lost productivity.
Ámbito científico
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
907 36 UMEA
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.